Full-Time

Clinical Development Associate Medical Director

Nephrology

Confirmed live in the last 24 hours

Vertex Pharmaceuticals

Vertex Pharmaceuticals

1,001-5,000 employees

Develops medicines for serious diseases

Compensation Overview

$198.3k - $297.4k/yr

+ Bonus + Equity Awards

Senior

Company Does Not Provide H1B Sponsorship

Boston, MA, USA

Hybrid-Eligible: work remotely up to two days per week; or work five days per week on-site with ad hoc flexibility.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Requirements
  • MD, DO or equivalent ex-US medical degree
  • 8 years of basic or clinical research experience in an academic or industry setting, or the equivalent combination of education and experience
  • Strong oral and written communication skills
  • Ability to work collaboratively in a fast-paced, team-based matrix environment and to function independently as appropriate
  • Global clinical research experience and experience interacting with regulatory authorities is a plus
  • Working familiarity with analysis of research data, biostatistics, pharmacology and pharmacokinetics, international standards for Good Clinical Practice (GCP), clinical study design, ethics committee/Institutional Review Board review, preparation of manuscripts, abstract/posters, and oral presentations, overall drug/device clinical development
  • Board certification/eligibility, as well as clinical training in a relevant medical specialty is highly desired
Responsibilities
  • Participates in the development of Study Protocols, Investigator's Brochures, Clinical Development Plans and other key documents in conjunction with other line functions and with minimal guidance
  • Serves on cross-functional Study Execution Teams (SET) for assigned trials, working with other team members to achieve efficient, high-quality study execution
  • Participates in the preparation of regulatory documents in support of regulatory submissions, including clinical section of INDs and CTAs, IND safety reports and annual reports for assigned trials, responses to regulatory authorities and Ethics Committees/IRBs, and other documents as appropriate
  • Provides scientific and clinical input to study-related documents and analysis plans including informed consent forms, clinical research forms, statistical analysis plans, clinical pharmacology analysis plans, and clinical study reports
  • Acts as liaison between Clinical Development and other internal groups at Vertex (e.g., Regulatory Affairs, Clinical Development Execution) for assigned studies
  • Represents Vertex to outside medical personnel in the development of clinical protocols, in study conduct, and in external reporting of study results
  • Performs other duties as assigned related to other aspects of Clinical Development
Desired Qualifications
  • Board certification/eligibility, as well as clinical training in a relevant medical specialty is highly desired
  • Global clinical research experience and experience interacting with regulatory authorities is a plus
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, focusing on conditions like cystic fibrosis. The company conducts extensive research and development to create new drugs, often collaborating with other biotech firms to enhance its therapeutic offerings. One of its notable products is ivacaftor, which has shown effectiveness in treating cystic fibrosis. Vertex differentiates itself from competitors through its commitment to scientific innovation and strategic partnerships that expand its research capabilities. The goal of Vertex Pharmaceuticals is to improve the quality of life for patients with severe and life-threatening conditions by bringing effective treatments to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Simplify Jobs

Simplify's Take

What believers are saying

  • EU approval for expanded cystic fibrosis treatment label boosts market penetration in Europe.
  • Partnership with Arbor Biotechnologies positions Vertex at the forefront of innovative treatments.
  • Recent investments indicate strong investor confidence in Vertex's growth potential.

What critics are saying

  • Recent layoffs suggest financial or strategic challenges impacting operational capabilities.
  • Discontinuation of diabetes asset indicates difficulty diversifying beyond cystic fibrosis.
  • Reliance on key products like ivacaftor makes Vertex vulnerable to market fluctuations.

What makes Vertex Pharmaceuticals unique

  • Vertex focuses on transformative medicines for serious diseases, like cystic fibrosis.
  • The company invests heavily in R&D and strategic partnerships for drug development.
  • Vertex's collaboration with Arbor Biotechnologies advances novel ex vivo engineered cell therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Company News

Pharmalive
Jun 11th, 2025
After axing diabetes asset, Vertex lays off 140 staff

After axing diabetes asset, Vertex lays off 140 staff.

PBN
Jun 10th, 2025
Vertex Pharmaceuticals to lay off 125 R.I. employees

PROVIDENCE - Vertex Pharmaceuticals Inc. is laying off 125 people in Rhode Island, according to a WARN notice filed with the R.I. Department of Labor and Training on June 8.

Buniversity
May 1st, 2025
VERTEX upset Grayhound for spot at BLAST Showdown

VERTEX locked in a first-place finish at Fortress OCE Masters Fall 2022 Finals in Melbourne to qualify for BLAST Premier Fall Showdown.

BioSpace
Apr 14th, 2025
Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis

Vertex researcher, Paul Negulescu Ph.D., receives the 2025 Canada Gairdner International Award for pioneering Research and discovery of medicines for Cystic Fibrosis.

Biz Owner Daily
Apr 7th, 2025
EU Approves Expanded Label for Vertex Pharmaceuticals' Cystic Fibrosis Treatment

Vertex Pharmaceuticals has received approval from the European Union to broaden the label for its cystic fibrosis treatment.